The FDA approved Corcept Therapeutics’ Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, clearing the therapy nearly four months early. The decision comes ahead of the scheduled PDUFA date and signals continued uptake for oral glucocorticoid-receptor antagonism in a heavily pretreated setting. Separately, industry coverage of early FDA wins placed Lifyorli alongside Denali Therapeutics’ accelerated approval for Hunter syndrome, highlighting how the agency’s recent rare-disease and oncology posture is translating into earlier-than-expected outcomes for sponsors. Clinically, the approval supports a multi-indication strategy for relacorilant in combination regimens and may shift competitive dynamics for next-line options in resistant disease.